Welcome to our dedicated page for Ligand Pharma SEC filings (Ticker: LGNDZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Ligand Pharma's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Ligand Pharma's regulatory disclosures and financial reporting.
Ligand Pharmaceuticals’ Chief Financial Officer Octavio Espinoza received equity awards as part of his compensation. He was granted stock options covering 23,527 shares of common stock at an exercise price of $202.55 per share, expiring on March 2, 2036. These options vest as to 12.5% of the underlying shares six months after the grant date, then in 42 substantially equal monthly installments.
He also received 4,933 restricted stock units (RSUs), each representing one share of common stock. The RSUs vest in three substantially equal annual installments on February 15, 2027, February 15, 2028, and February 15, 2029, subject to continued service. Delivery of shares on each vesting date will be deferred under the company’s Nonqualified Deferred Compensation Plan. Following the RSU grant, he directly owns 37,945 shares of common stock.
Ligand Pharmaceuticals Chief Executive Officer Todd C. Davis reported equity awards consisting of stock options and restricted stock units. He received options to buy 50,058 shares of common stock at an exercise price of $202.55 per share, expiring on March 2, 2036.
The option grant vests as to 12.5% of the underlying shares six months after the grant date and then in 42 substantially equal monthly installments. Davis also received 10,495 restricted stock units, each representing one share of common stock, which vest in three equal annual installments on February 15, 2027, February 15, 2028, and February 15, 2029, with delivery of shares deferred under a company plan.
Ligand Pharmaceuticals’ CLO & Secretary Andrew Reardon reported equity compensation awards. He received 4,513 shares of common stock as a grant, bringing his direct common stock holdings to 41,382 shares.
He was also granted an option for 21,525 shares at an exercise price of 202.55 per share. The option vests 12.5% six months after the March 2, 2026 grant date and then in 42 equal monthly installments. The 4,513-share grant represents restricted stock units that vest in three equal annual installments on February 15, 2027, February 15, 2028, and February 15, 2029, with delivery of shares deferred under a company plan.
Ligand Pharmaceuticals director Stephen L. Sabba reported an open-market sale of 1,000 shares of Common Stock. The shares were sold on March 23, 2026 at an average price of $207.8727 per share, as detailed across multiple small trades that day.
After this transaction, Sabba directly holds 32,793 shares of Ligand Pharmaceuticals Inc. A footnote explains that this total includes 1,209 previously reported restricted shares that were granted in 2025 and are expected to vest in full within six months from the reported date.
LGND reported an insider sale. Stephen L. Sabba reported the sale of 2,034 common shares on 03/03/2026 with an aggregate figure shown as $409,851.00 in the filing. The notice also records an earlier exercised block of 1,000 shares on 03/05/2024 noted as "Exercised Shares" for cash.
Ligand Pharmaceuticals’ Chief Legal Officer and Secretary Andrew Reardon reported a set of planned insider transactions in company stock. On March 4, 2026, he exercised employee stock options for 5,000 shares of common stock and then sold 5,000 common shares in a series of open-market trades.
The sales were executed at weighted-average prices disclosed in ranges between approximately $197.58 and $208.97, under a Rule 10b5-1 trading plan adopted on November 24, 2025. After these transactions, Reardon directly holds 36,869 common shares and 54,444 options, with the underlying option grant vesting over time.
Ligand Pharmaceuticals’ Chief Financial Officer Octavio Espinoza reported option exercises and share sales in company stock. On March 4, 2026, he exercised employee stock options covering 2,073 shares of common stock and then sold 13,423 shares in open-market transactions.
The sales were executed at weighted-average prices generally between $198.37 and $208.95 pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 19, 2025. After these transactions, he directly owned 21,662 shares of Ligand common stock.
Ligand Pharmaceuticals director Stephen L. Sabba exercised a stock option for 2,034 common shares at $69.51 per share and on the same day sold 2,034 shares at $201.50 per share in an open-market transaction. He now directly holds 33,793 common shares.
Ligand Pharmaceuticals director John W. Kozarich reported open-market sales of company common stock. On March 2, 2026, he sold a total of 467 shares in six separate transactions under a written trading plan adopted on March 7, 2025 in accordance with Rule 10b5-1.
The reported weighted-average prices for these sales ranged from about $197 to $203 per share, based on detailed price ranges in the filing. After completing the transactions, Kozarich directly owned 42,720 shares of Ligand Pharmaceuticals common stock.